Obesity induced cardiomyopathy involves chronic and sustained inflammation. Toll–like receptor 4 (TLR4) signaling pathway can associate innate immunity with obesity. Myeloid differentiation primary response 88 (MyD88), an indispensable down-stream adaptor molecule of TLR4, has been reported to mediate obesity complications.
However, whether inhibition of MyD88 can mitigate obesity-induced heart injury remains unclear. LM8, a new MyD88 inhibitor, exhibits prominent anti-inflammatory activity in LPS treated macrophages. In the present study, the protective effects of LM8 on high fat diet (HFD)-induced heart injury were assessed in a mouse model of obesity.
[Linking template=”default” type=”products” search=”SKT-106-480″ header=”2″ limit=”180″ start=”2″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””]